Skip to main content
. Author manuscript; available in PMC: 2011 Jun 9.
Published in final edited form as: Anesthesiology. 2009 Mar;110(3):660–672. doi: 10.1097/ALN.0b013e3181986a9a

Figure 3.

Figure 3

Effect of ritonavir/indinavir on first-pass and hepatic CYP3A activity, assessed using alfentanil as a CYP3A probe. Pupil diameter change from baseline (miosis) was used as a surrogate for alfentanil plasma concentrations. Shown is dose-normalized miosis after (A) 43 and 23 μg/kg oral alfentanil at control and ritonavir/indinavir sessions, respectively, and (B) 15 and 10 μg/kg IV alfentanil at control and ritonavir/indinavir sessions, respectively. Each data point is the mean ± SD (n=12). Some SD are omitted for clarity.